NCT02568800

Brief Summary

It is advocated that prolonged infusion of beta-lactamic antibiotics provides better bactericidal effect. The aim of the present study is to randomize patients a to extended cefepime infusion regimen (lasting four hours) or to a usual infusion regimen (not lasting more than thirty minutes) and evaluate the clinical efficacy of this theoretical pharmacokinetic advantage.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
134

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Oct 2015

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

October 2, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 6, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

October 16, 2015

Status Verified

October 1, 2015

Enrollment Period

5 months

First QC Date

October 2, 2015

Last Update Submit

October 15, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Death

    Death in 30 days since randomization

    30 days

Secondary Outcomes (7)

  • Death

    14 days

  • Duration of hospital stay

    30 days since randomization

  • Intensive care unit (ICU) admission

    30 days since randomization

  • Duration of intensive care unit (ICU) stay

    30 days since randomization

  • Treatment change

    3 days after randomization

  • +2 more secondary outcomes

Study Arms (2)

Prolonged Cefepime Infusion

EXPERIMENTAL

Cefepime infusions should last 4 hours at least

Drug: Prolonged Cefepime Infusion

Usual Cefepime Infusion

ACTIVE COMPARATOR

Cefepime infusion should last no more than 30 minutes

Drug: Usual Cefepime Infusion

Interventions

Cefepime infusion should last at least 4 hours with the aide of an infusion bomb

Also known as: Estended Cefepime Infusion
Prolonged Cefepime Infusion

Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes

Also known as: Regular Cefepime Infusion
Usual Cefepime Infusion

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Urinary tract infection after 48-72 hours of hospital stay
  • Respiratory tract infection after 48-72 hours of hospital stay
  • Catheter related urinary tract infection after 48-72 hours of hospital stay
  • Urinary or respiratory infections not responding to a narrower spectrum antibiotic
  • Isolation of bacteria sensible to cefepime in blood, urine or sputum in a clinical context of infection

You may not qualify if:

  • Glomerular filtration rate lower than 30 ml.min/1,73m²
  • ICU admission for at least 72 hours before randomization
  • Neutrophil count lower than 1000 cels per mm³
  • Hematologic malignancy, bronchiectasis and cystic fibrosis
  • Patients allergic to cefepime
  • Concomitant treatment to another infectious disease
  • Central nervous system, cutaneous or intrabdominal infections
  • Solid organ transplantation
  • HIV with a cluster differentiation 4 (CD4) lower than 100 cels per mm³

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

RECRUITING

MeSH Terms

Conditions

Urinary Tract InfectionsRespiratory Tract Infections

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesRespiratory Tract Diseases

Study Officials

  • Eduardo Sprinz

    Hospita de Clínicas de Porto Alegre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

André Dias Américo

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 2, 2015

First Posted

October 6, 2015

Study Start

October 1, 2015

Primary Completion

March 1, 2016

Study Completion

September 1, 2016

Last Updated

October 16, 2015

Record last verified: 2015-10

Locations